1. Home
  2. GVH vs APRE Comparison

GVH vs APRE Comparison

Compare GVH & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

HOLD

Current Price

$6.00

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.84

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVH
APRE
Founded
2016
2006
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.6M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
GVH
APRE
Price
$6.00
$0.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$80.00
$4.10
AVG Volume (30 Days)
150.7K
291.1K
Earning Date
02-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102,768.97
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.55
52 Week High
$10.74
$2.22

Technical Indicators

Market Signals
Indicator
GVH
APRE
Relative Strength Index (RSI) 85.92 49.89
Support Level $4.02 $0.57
Resistance Level N/A $0.98
Average True Range (ATR) 0.65 0.08
MACD 0.23 -0.01
Stochastic Oscillator 89.05 19.60

Price Performance

Historical Comparison
GVH
APRE

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: